Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 24,09:00-12:00
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
Stay tuned
Planner/Meeting Hosts
Keiji Kawamoto:Representative, Kawamoto BioBusiness Partners / Senior Advisor, Shanghai Deband Law Firm
Ruiping Dong:Founder and Chairman, RealOne Medicines
09:00-09:05 Opening Remarks
Zhengqian Niu: Chairman, Internationalization Committee, China Pharmaceutical Enterprises Association (CPEA)
09:05-09:30 Latest Trends and Innovation Environment in Japan's New Drug Market
Yuji Kato: Editor in Chief, Nikkei Biotechnology & Business, Nikkei Business Publications, Inc.
09:30-09:55 How Does Japan Join a China-Dominant Clinical Trial to Get Approval by PMDA?
Fugen Li: SVP, Haihe Biopharma
09:55-10:20 Practical Guidance for Initiating Clinical R&D of Chinese Innovative Drugs in Japan
Toshimi Nouchi: Executive Officer, Global Business Promotion, EPS Corporation
10:20-10:45 MNC Reverse Roadshow
Kazunari Tsukamoto: SVP and Global Head of BD, Astellas
10:45-11:10 Collaborative Synergy with Japanese R&D Institutions and Biopharma Enterprises
Hiroki Narita: CEO, Daiwa Corporate Investment (DCI)
11:10-12:00 Panel Discussion: Global Footprint Strategy for Chinese Innovative Drugs — How to Leverage Japan's Market to Boost Overseas Expansion Strategies
Ruiping Dong(Moderator):Founder and Chairman, RealOne Medicines
Yoshiaki Maruyama:Director, Regulatory Review Department for Regenerative Medical Products, PMDA, Japan
Tetsuya Hagiwara:Vice President, Head of BD, Japan, Kyowa Kirin
Jianghu Piao:General Manager, International BD, Corporate Strategy, Toho Holding Co., Ltd.; Chairman, Hubei Gongchuang Pharmaceutical
Anbo Xiang:CMO of Non-Oncology, CSPC Pharmaceutical Group
Xiao Han:Director, Tigermed